Cargando…
Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems
Despite decades of research and billions in global investment, there remains no preventative or curative treatment for any neurodegenerative condition, including Parkinson’s disease (PD). Arguably, the most promising approach for neuroprotection and neurorestoration in PD is using growth factors whi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543245/ https://www.ncbi.nlm.nih.gov/pubmed/33896851 http://dx.doi.org/10.3233/JPD-212662 |
_version_ | 1784589601815396352 |
---|---|
author | Jarrin, Sarah Hakami, Abrar Newland, Ben Dowd, Eilís |
author_facet | Jarrin, Sarah Hakami, Abrar Newland, Ben Dowd, Eilís |
author_sort | Jarrin, Sarah |
collection | PubMed |
description | Despite decades of research and billions in global investment, there remains no preventative or curative treatment for any neurodegenerative condition, including Parkinson’s disease (PD). Arguably, the most promising approach for neuroprotection and neurorestoration in PD is using growth factors which can promote the growth and survival of degenerating neurons. However, although neurotrophin therapy may seem like the ideal approach for neurodegenerative disease, the use of growth factors as drugs presents major challenges because of their protein structure which creates serious hurdles related to accessing the brain and specific targeting of affected brain regions. To address these challenges, several different delivery systems have been developed, and two major approaches—direct infusion of the growth factor protein into the target brain region and in vivo gene therapy—have progressed to clinical trials in patients with PD. In addition to these clinically evaluated approaches, a range of other delivery methods are in various degrees of development, each with their own unique potential. This review will give a short overview of some of these alternative delivery systems, with a focus on ex vivo gene therapy and biomaterial-aided protein and gene delivery, and will provide some perspectives on their potential for clinical development and translation. |
format | Online Article Text |
id | pubmed-8543245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-85432452021-11-10 Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems Jarrin, Sarah Hakami, Abrar Newland, Ben Dowd, Eilís J Parkinsons Dis Review Despite decades of research and billions in global investment, there remains no preventative or curative treatment for any neurodegenerative condition, including Parkinson’s disease (PD). Arguably, the most promising approach for neuroprotection and neurorestoration in PD is using growth factors which can promote the growth and survival of degenerating neurons. However, although neurotrophin therapy may seem like the ideal approach for neurodegenerative disease, the use of growth factors as drugs presents major challenges because of their protein structure which creates serious hurdles related to accessing the brain and specific targeting of affected brain regions. To address these challenges, several different delivery systems have been developed, and two major approaches—direct infusion of the growth factor protein into the target brain region and in vivo gene therapy—have progressed to clinical trials in patients with PD. In addition to these clinically evaluated approaches, a range of other delivery methods are in various degrees of development, each with their own unique potential. This review will give a short overview of some of these alternative delivery systems, with a focus on ex vivo gene therapy and biomaterial-aided protein and gene delivery, and will provide some perspectives on their potential for clinical development and translation. IOS Press 2021-09-22 /pmc/articles/PMC8543245/ /pubmed/33896851 http://dx.doi.org/10.3233/JPD-212662 Text en © 2021 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Jarrin, Sarah Hakami, Abrar Newland, Ben Dowd, Eilís Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems |
title | Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems |
title_full | Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems |
title_fullStr | Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems |
title_full_unstemmed | Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems |
title_short | Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems |
title_sort | growth factor therapy for parkinson’s disease: alternative delivery systems |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543245/ https://www.ncbi.nlm.nih.gov/pubmed/33896851 http://dx.doi.org/10.3233/JPD-212662 |
work_keys_str_mv | AT jarrinsarah growthfactortherapyforparkinsonsdiseasealternativedeliverysystems AT hakamiabrar growthfactortherapyforparkinsonsdiseasealternativedeliverysystems AT newlandben growthfactortherapyforparkinsonsdiseasealternativedeliverysystems AT dowdeilis growthfactortherapyforparkinsonsdiseasealternativedeliverysystems |